NEWARK, Calif.–()–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the promotion of Dustin Sjuts to the role of Chief Commercial Officer, Aesthetics & Therapeutics, reporting directly to Mark Foley, Revance’s President and Chief Executive Officer. In his new role, Mr. Sjuts will be responsible for all of the company’s commercial operations and launch activities in preparation for DAXI’s anticipated approval in the second half of 2020.

“We are pleased to announce the appointment of Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics, as he is an accomplished leader in the aesthetics industry with more than 20 years of global experience in commercial operations, business development, practice integration, pricing & reimbursement strategy, consumer engagement and brand building,” said Mark Foley, President and Chief Executive Officer of Revance. “Over the last year, as Head of Commercial, Aesthetics & Therapeutics, Dustin has done a great job of mapping out our go-to-market strategy while also putting in place an outstanding commercial leadership team with decades of aesthetic, therapeutic, and product launch expertise. Dustin’s focus is on positioning Revance to take a meaningful share in the $1 billion U.S. aesthetics neuromodulator market once DAXI is approved, while also laying the groundwork for unlocking DAXI’s considerable opportunity in therapeutics.”

Mr. Sjuts’ track record spans medical devices, aesthetics, therapeutics, and consumer goods, and includes successfully building advanced commercial and operational enterprises, spearheading business development, designing innovative consumer strategies, and leading product launches across established and emerging markets. Prior to joining Revance, he held U.S. and global-based leadership positions spanning aesthetics, therapeutics and consumer goods at Nestle Skin Health in both the U.S. and China as well as in aesthetics and ophthalmology at Allergan.

“I am delighted to step into the Chief Commercial Officer role at Revance, as we pioneer new innovations in neuromodulator products to fundamentally redefine the category,” said Sjuts. “We are committed to creating an offering and experience that exceeds patient and healthcare provider expectations, unlocks category growth, and is wholly differentiated in the market.”

About Revance Therapeutics, Inc.

Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DAXI in forehead lines and lateral canthal lines (crow’s feet), as well as in three therapeutic indications – cervical dystonia, adult upper limb spasticity and plantar fasciitis, with plans to study migraine. Beyond DAXI, Revance has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
BOTOX® is a registered trademark of Allergan, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates, including but not limited to initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; including our pre-commercialization plans; and statements about the timing and our ability to obtain regulatory approval and launch products, including with respect to DAXI for Injection to treat glabellar (frown) lines; potential benefits of our drug product candidates and our technologies; and our ability to compete in the neuromodulator market. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations and achieve our goals; our plans to research, develop, and commercialize our drug product candidates; our ability to successfully compete with treatments and therapies, our ability to achieve, and the rate and degree of market acceptance and adoption of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully manufacture and commercialize our drug product candidates and the timing of commercialization activities; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance’s periodic filings with the Securities and Exchange Commission (the “SEC”), including factors described in the section entitled “Risk Factors” of our quarterly report on Form 10-Q filed November 4, 2019. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

Source

- Advertisement -